MilliporeSigma Launches Parteck? MXP Excipient for Increased Solubility
- Enhances solubility of active pharmaceutical ingredients with poor bioavailability
- Enables higher amount of API loading with excellent stability
Billerica, Massachusetts, December 2, 2016 — MilliporeSigma, a leading science and technology company, today introduced Parteck? MXP, a polyvinyl alcohol-based excipient that enhances solubility of a wide range of active pharmaceutical ingredients (APIs) with poor bioavailability.
Parteck? MXP excipient maintains stability at temperatures above 200 degrees Celsius, making it well-suited for hot melt extrusion (HME), a process used by drug manufacturers to enhance the solubility and bioavailability of APIs. The new excipient can achieve drug loads of 30 percent or more, while other excipients may be limited to 10-15 percent in HME. Drug load is a measure of the amount of API by weight that can be combined with the excipient.
"More than 90 percent of drugs in the pharmaceutical pipeline have solubility issues that lead to poor bioavailability, a key factor in the success of a drug candidate," said Andrew Bulpin, Head of Process Solutions Strategic Marketing & Innovation, MilliporeSigma. "Parteck? MXP excipient is the latest addition to our comprehensive excipients portfolio and allows our customers to address solubility challenges that otherwise might have prevented promising and potentially life-changing drug candidates from progressing through the pipeline."
The new excipient has been successfully tested on eight commonly used and poorly soluble APIs, including ibuprofen, indomethacin and itraconazole, and can be used in formulations for both immediate and sustained release.
In contrast with more complex excipients, Parteck? MXP excipient uses simple chemistry, potentially streamlining regulatory processes. The polymer used in Parteck? MXP is generally recognized as safe (GRAS)i by the U.S. Food and Drug Administration and complies with U.S. Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia for excipient monographs.
Parteck? MXP excipient is an expansion of MilliporeSigma’s portfolio of products that enhance bioavailability by improving poor aqueous solubility and controlled release. After rigorous testing, Parteck? MXP excipient will also be incorporated into the company’s Emprove? program. Using this program, customers have instant, online access to regulatory and technical information about the excipient, more than 400 other chemicals, filters and single-use components to facilitate risk assessment and qualification processes.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.kvqryg.live/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the ?Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, and Baylor College of Medicine, Houston, Texas, USA, today announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, designed..